Skip to main content
OpenTrials
Completed

NCT Number: NCT04521023

A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ajou University Hospital, Suwon, Gyeonggi-do, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • over 19 years old
  • Agreement with written informed consent
  • Hypertensive Patients

Exclusion criteria

  • Patients with secondary hypertension
  • Participated in other trial within 30 days
  • In investigator's judgement

Treatment and study plan

Cantabell Tab

Drug

Patients assigned to experimental group are treated with Cantabell Tab

Candemore Plus Tab

Drug

Patients assigned to experimental group are treated with Candemore Plus Tab

Primary outcomes

  1. cSBP(central Systolic Blood Pressure)

    Time frame: change after 8 weeks compared to baseline

    Average cSBP change after 8 weeks compared to baseline

Secondary outcomes

  1. cDBP(central Diastolic Blood Pressure)

    Time frame: change after 8 weeks compared to baseline

    Average cDBP change after 8 weeks compared to baseline

  2. sitSBP(sitting Systolic Blood Pressure)

    Time frame: change after 8 weeks compared to baseline

    Average sitSBP change after 8 weeks compared to baseline

  3. sitDBP(sitting Diastolic Blood Pressure)

    Time frame: change after 8 weeks compared to baseline

    Average sitDBP change after 8 weeks compared to baseline

Sponsors and collaborators

Lead sponsor

Chong Kun Dang Pharmaceutical

Industry

Registry information

Official study title

A Randomized, Double-blind, Non-inferiority, Multi-center, Phase 4 Trial to Evaluate the Blood Pressure Lowering Effect of a Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Aug 20, 2020
Registry last updated
Aug 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.